Shanghai Hequan Pharmaceutical R&D Co., Ltd.

Hequan Pharmaceutical is a WuXi AppTec group company located in both China and the United States, serving the life science industry with exceptional capabilities and technology platforms for small molecule innovative drug R&D and manufacturing. As a leading enterprise in the global Contract Development and Manufacturing Organization (CDMO) field, Hequan Pharmaceutical is committed to providing global partners with efficient, flexible, and high-quality one-stop solutions from small molecule Active Pharmaceutical Ingredients (APIs) to formulations. Hequan boasts the world's largest chemical process team, with over 1,000 experienced researchers and scientists offering comprehensive solutions, including: synthesis route screening, process development, optimization and scale-up, determination of starting materials, intermediates, and API quality control strategies, and process validation. Our state-of-the-art production facilities can manufacture intermediates and innovative APIs from kilogram to ton scale under cGMP conditions. Enormous production capacity: The total reactor volume at our Shanghai Jinshan plant is 400 m³, and the new Changzhou plant will add over 1,000 m³ of reactor volume. Overall, we provide clients with 200 reactors ranging from 5L to 20,000L to ensure rapid production. International standard quality systems: The Shanghai Jinshan plant has been approved by 8 global regulatory agencies, including the US FDA, China CFDA, EU EMA, Australia TGA, Health Canada, Japan MHLW, Swissmedic, and New Zealand MPI, and can produce innovative APIs and intermediates. Our formulation facility in Shanghai possesses top-tier R&D and production capabilities, offering formulation development from preclinical to commercialization, as well as production, packaging, and labeling services for clinical batches, including: collaboration with WuXi AppTec's medicinal chemistry, DMPK, and biology departments for rapid IND development, expertise in developing poorly soluble drugs and pediatric formulations, and extensive experience in oral solid dosage form production, with the facility approved by the US FDA and Swedish MPA.